Safety of anacetrapib in patients with or at high risk for coronary heart disease.
New England Journal of Medicine.
Times cited: 634
Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib.
American Heart Journal.
Times cited: 74